yuri_pikover_savara

Savara Pharmaceuticals appoints two board members

pharmafile | December 9, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Joseph McCracken, Pikover, savara 

Speciality pharma firm Savara Pharmaceuticals has appointed Dr Joseph McCracken and Yuri Pikover to its board of directors.

McCracken has more than 25 years of experience working with with biotech and pharma companies. Most recently he was Global head of Business Development & Licensing at Roche.

Prior to joining Roche McCracken held the position of vice president of Business Development at Genentech for more than a decade.

Advertisement

Pikover (pictured) is a managing director of 37 Technology Ventures, a boutique venture fund focussing on growing startups, and currently serves on the boards of numerous companies.

“We are delighted to welcome Joseph and Yuri to our board of directors at an exciting time for the company,” said Savara’s chief executive Rob Neville. “The two bring a breadth of business development and public company experience to our team that will help achieve our long term growth objectives.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content